The deal supports Elligo’s aim to create a technology-driven, healthcare-enabling research organisation for enhanced clinical research. Elligo also intends to enable easy access for quick enrolment and expedited clinical trials.
Root Health’s AI virtual assistant is complementary to Elligo’s IntElligo Research Stack.
Root Health CEO Raj Sharma said: “Root Health was built to improve the patient’s experience in clinical trials while accelerating patient recruitment.
“Together, we will build stronger healthcare communities and bring clinical research as care to more patients.”
Elligo has also appointed Miranda Mann Porter as its COO. Porter comes with experience in central nervous system therapeutics, clinical development programmes, and Phase I-IV trials.
Porter previously worked with Syneos Health, including as executive vice-president and general manager of Asia Pacific.
Elligo Health Research CEO John Potthoff said: “We look forward to continuing to expand our leadership team, technologies, and service offerings as we further our mission to ensure that all patients have access to clinical trials as a care option.”
Last month, Elligo partnered with Laguna Clinical Research Associates (LCRA) to expand access to clinical trials in diverse communities. The companies agreed to work with more than 20 urgent care locations in these communities.
In a separate development, IQVIA subsidiary Q2 Solutions has partnered with Tasso to boost decentralised clinical trials. The partners will develop diagnostic tests.
Q2 Solutions is a clinical trial laboratory services organisation, while Tasso provides clinical-grade, patient-centred blood testing at home.
Tasso’s devices are being used by pharmaceutical companies for research and development across several trials.